Adicet Bio finishes final patient visits in lupus CAR-T study, plans September data

Adicet Bio, Inc. announced on September 1, 2026 that it completed the last patient visit for a planned Phase 1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus, with or without lupus nephritis.¹ The company said it expects to report topline data in September 2026,¹ and plans to hold an investor webcast once that data is released to walk through results and next steps.¹

The analysis draws on 22 SLE patients, with or without lupus nephritis, each followed for at least six months; 13 of those patients have at least a year of follow-up data.¹ Adicet also said it is developing a potential registrational trial design after discussions with the FDA, with more detail expected alongside the upcoming clinical update.¹ Separately, the company noted it has expanded prula-cel dosing to the outpatient setting following alignment with the FDA, covering lupus nephritis and other SLE patients in current and future studies.¹ A systemic sclerosis update is expected in the fourth quarter of 2026.¹

On the oncology side, the FDA cleared Adicet's IND for ADI-212, a treatment candidate for metastatic castration-resistant prostate cancer, in August 2026.¹ The company plans to begin enrollment in the fourth quarter of 2026.¹ ADI-212 is described as an off-the-shelf, gene-edited cell therapy designed with an added immune-stimulating molecule meant to improve tumor targeting, durability of tumor killing, and modulation of the tumor microenvironment.¹

Adicet is also building out an in vivo CAR-T platform, with preclinical work in multiple myeloma, non-Hodgkin's lymphoma, and solid tumor indications,¹ and the company expects its first candidate from that portfolio to reach clinical development in the second half of 2027.¹